Theralase Technologies Inc. TLT.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · theralase.com
Theralase Technologies Inc. is a clinical-stage pharmaceutical company focused on the research, development, and commercialization of light-activated photo dynamic compounds to treat cancers, bacteria, and viruses. The company's lead program, TLD-1433, is in Phase II clinical trials for the treatment of Bacillus Calmette Guérin-unresponsive non-muscle invasive bladder cancer. It also operates a Device Division marketing super-pulsed laser technology for chronic pain conditions, based in Toronto, Ontario.
Key ratios
FreeCashFlowOnSale TTM -2.61
FreeCashFlowOnSale 2024 -3.24
FreeCashFlowOnSale 2023 -3.84
FreeCashFlowOnSale 2022 -4.54
ReturnOnAssets TTM -0.89
ReturnOnAssets 2024 -0.82
ReturnOnAssets 2023 -0.77
ReturnOnAssets 2022 -0.65
ReturnOnEquity TTM -2.69
ReturnOnEquity 2024 -2.14
ReturnOnEquity 2023 -1.83
ReturnOnEquity 2022 -1.28
TotalRevenueYoYGrowth TTM 0.01
TotalRevenueYoYGrowth 2024 -0.03
TotalRevenueYoYGrowth 2023 -0.06
TotalRevenueYoYGrowth 2022 0.46
Recent news
Theralase Receives Receipt for C$100 Million Base Shelf Prospectus
2026-06-30 · Newsfile
Theralase® Releases Q1 2026 Financial Statements
2026-05-29 · Newsfile Corp
Theralase® Closes C$4.8 Million Offering
2026-05-20 · Newsfile Corp